Hayashi Naomi, Fukada Ippei, Ohmoto Akihiro, Yamazaki Masumi, Wang Xiaofei, Hosonaga Mari, Takahashi Shunji
Department of Genomic Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto, Tokyo, 135-8550, Japan.
Medical Oncology, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Discov Oncol. 2022 Oct 19;13(1):109. doi: 10.1007/s12672-022-00574-2.
Performance status (PS) is widely used as an assessment of general condition in patients before performing comprehensive genomic profiling (CGP). However, PS scoring is dependent on each physician, and there is no objective and universal indicator to identify appropriate patients for CGP. Overall, 263 patients were scored using the modified Glasgow prognostic score (mGPS) from 0 to 2 based on the combination of serum albumin and c-reactive protein (CRP): 0, albumin ≥ 3.5 g/dl and CRP ≤ 0.5 mg/dl; 1, albumin < 3.5 g/dl or CRP > 0.5 mg/dl; and 2, albumin < 3.5 g/dl and CRP > 0.5 mg/dl. Overall survival was compared between mGPS 0-1 and mGPS 2 groups. The prognosis of patients with PS 0-1 and mGPS 2 was also evaluated. Thirty-nine patients (14.8%) were mGPS 2. Patients with mGPS 2 had significant shorter survival (14.7 months vs 4.6 months, p < 0.01). Twenty-eight patients were PS 0-1 and mGPS 2, and their survival was also short (5.6 months). Evaluation of mGPS is a simple and useful method for identifying patients with adequate prognosis using CGP.
在进行综合基因组分析（CGP）之前，体能状态（PS）被广泛用作评估患者总体状况的指标。然而，PS评分依赖于每位医生，且没有客观通用的指标来确定适合进行CGP的患者。总体而言，基于血清白蛋白和C反应蛋白（CRP）的组合，使用改良格拉斯哥预后评分（mGPS）对263例患者进行了0至2分的评分：0分，白蛋白≥3.5g/dl且CRP≤0.5mg/dl；1分，白蛋白<3.5g/dl或CRP>0.5mg/dl；2分，白蛋白<3.5g/dl且CRP>0.5mg/dl。比较了mGPS 0 - 1组和mGPS 2组的总生存期。还评估了PS 0 - 1和mGPS 2患者的预后。39例患者（14.8%）为mGPS 2。mGPS 2的患者生存期显著缩短（14.7个月对4.6个月，p<0.01）。28例患者为PS 0 - 1且mGPS 2，他们的生存期也较短（5.6个月）。评估mGPS是一种使用CGP识别预后良好患者的简单且有用的方法。
